CN101229331B - 一种治疗厌食症的药物及其制备方法 - Google Patents
一种治疗厌食症的药物及其制备方法 Download PDFInfo
- Publication number
- CN101229331B CN101229331B CN2008100650432A CN200810065043A CN101229331B CN 101229331 B CN101229331 B CN 101229331B CN 2008100650432 A CN2008100650432 A CN 2008100650432A CN 200810065043 A CN200810065043 A CN 200810065043A CN 101229331 B CN101229331 B CN 101229331B
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- rhizoma
- radix
- endothelium corneum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 229940079593 drug Drugs 0.000 title claims abstract description 28
- 208000022531 anorexia Diseases 0.000 title abstract description 9
- 206010061428 decreased appetite Diseases 0.000 title abstract description 9
- 238000000034 method Methods 0.000 title description 6
- 240000008042 Zea mays Species 0.000 claims abstract description 26
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 26
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 26
- 235000005822 corn Nutrition 0.000 claims abstract description 26
- 244000113306 Monascus purpureus Species 0.000 claims description 27
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 27
- 210000003038 endothelium Anatomy 0.000 claims description 27
- 229940057059 monascus purpureus Drugs 0.000 claims description 27
- 210000000582 semen Anatomy 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 5
- 208000003643 Callosities Diseases 0.000 claims description 4
- 235000005903 Dioscorea Nutrition 0.000 claims description 4
- 241000234273 Dioscorea Species 0.000 claims description 4
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 4
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 4
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract description 3
- 230000031891 intestinal absorption Effects 0.000 abstract description 2
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000003571 opsonizing effect Effects 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 108010008364 Melanocortins Proteins 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002865 melanocortin Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 208000022530 polyphagia Diseases 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical group C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 208000008630 Sialorrhea Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004317 gizzard Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- 229960001669 kinetin Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- -1 zeaxanthin carotenoid Chemical class 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 241000639924 Aspergillaceae Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,提供了一种治疗厌食症的药物,是由下列重量份的原料药制成:玉米9~10份、山药9~10份、鸡内金3~4份、白术3~4份、红曲2~3份,大黄0.5~1份、黑豆2~3份。本发明药物集养生保健、治疗、康复于一体,可促进胃受纳,脾健运,肠吸收,通过调理人肠道菌群而达到有效治疗厌食症的目的。
Description
技术领域
本发明属于中药领域,尤其涉及一种治疗厌食症的药物及其制备方法。
背景技术
厌食症与善饥症过去被认为是精神疾患,瑞典斯德哥尔摩的卡洛琳达学院塞格·菲迪索夫依据某种类型感染和某些精神疾患相关症状,将两种常见精神病神经性厌食和神经性食欲过盛或善饥相联系起来分析研究。菲迪索夫博士研究结果证实,人体自身免疫系统有缺陷会引起一种称为黑皮质素(melancorrin)的激素分泌不正常,这就是发生厌食和善饥症的病因。黑皮质素是一种小的蛋白分子,它在人体脑部神经细胞中传递信息。黑皮质素参与调节多种复杂行为举止,包括社交能力,对压力的反应,以及对摄取食物的喜好,所以它可以轻而易举地干扰或影响厌食症或善饥症的发生,暴饮暴食会扰乱生物钟,生物钟与代谢是密切相关。这两种病症的自身免疫水平改变原因现在尚不清楚,其初步线索倾向于是微生物所引起,即细菌和病毒使宿主免疫系统发生混乱,例如,两种常见胃肠道细菌:大肠杆菌和幽门螺旋杆菌,还有流感病毒。受黑皮质素或其它传递信息分子调节,人会发生一系列行为改变,过去曾被怀疑一种精神疾患。过去厌食症与善饥症大多通过服用精神药物来治疗,而服用精神药物通常会对身体产生比较大的副作用,不利于人体健康。目前,通过治疗患者的细菌或病毒感染性疾病,来治疗厌食症和善饥症将成为一个新的治疗方向。
发明内容
为解决上述问题,本发明的目的在于提供一种能治疗厌食症的药物组合物。
本发明的另一个目的在于提供一种该药物组合物的制备方法。
本发明药物选择玉米、鸡内金、山药、白术、红曲、大黄和黑豆进行组合,将这些药物组合使得药物功效产生协同作用,从而能有有效治疗厌食症和善饥症。
玉米:性味,1、《本草纲目》:甘,平,无毒;2、《本草纂要》:甘,淡,微寒;3、《本草撮要》:入手,足阳明经。功用主治:1、《本草纲目》:调中开胃;2、《医林纂要》:益肺宁心;3、《本草推陈》:健胃剂,煎服亦有利尿之功。成分:种子含有淀粉达61.2%,脂肪:4.2-4.75%,生物碱类约0.21%,尚有维生素B1、B2、B6、烟酸、泛酸、生物素等B族维生素,玉米黄素(zeaxanthin)等类胡萝卜素,槲皮素,异槲皮甙,果胶(中含半乳糖醛酸)等;玉米油的脂肪酸组成,不同品种差别较大,其百分比为棕榈酸6-22%、硬脂酸0.5-15%、油酸14-64%、亚油酸19-71%;尚含硫脂,主为6-硫酸奎诺糖酰甘油二酯(6-sulfoquinovosyldiglyceride);玉米嘌呤(zeatin),是一种动力精(kinetin,Cylokinin),有促进植物细胞分裂作用。
鸡内金:性味甘,平。归入脾胃经。《医学衷中参西录》:鸡内金,鸡之脾胃也,中有瓷石、铜、铁皆能消化,其善化淤积可知,<脾胃>居中焦以升降气化,若有淤积,气化不能升降,是以易致胀满,用鸡内金为脏器疗法,若再与白术等分并用,为消化淤积之要药,更为健补脾胃之妙品,脾胃健壮,益能运化药力以消积也,不但能消脾胃之积,无论脏腑何处有积,鸡内金皆能消之。成分:含胃激素、角蛋白等,组织化学方法显示砂囊的角蛋白样膜含一种糖蛋白,它的半胱氨酸的含率低于一般上皮角蛋白。每100毫克砂囊含有:维生素B1 100微克、维生素B2 200微克,尼克酸7毫克,抗坏血酸5毫克。
山药:性味甘、平,入肺、脾、肾经。健脾、补肺、固肾、益精。《药性论》:补五劳七伤;《本草求真》:山药,本属食物,古人用入汤剂,谓其补脾益气除热;《本草经读》:山药,能补肾填精,精足则阴强、目明、耳聪。凡上品俱是寻常服食之物,非治病之药,含大量益生元,益生元是益生菌赖以生存的食物,能有效减轻便秘,降低肠道pH值,恢复肠道细菌平衡。近期研究,山药可增加肝的抗氧化活性,降低肝功能指数,脂质过氧化及肝脏DNA伤害,山药有保肝功能。
白术:性味苦甘、温。入脾胃经。补脾益肾、燥湿、和中。《日华子本草》:治一切风疾,五劳七伤,冷气腹胀。白术能通大便,含挥发油1-4%,主要成分为苍术醇、苍术酮等,并含有维生素A。
红曲:性味甘,温。入肝、脾、大肠经。《饮膳正要》:“健脾,益气,温中。”为曲霉科真菌紫色红曲霉寄生在粳米上而成红曲米。红曲是发酵食品,能促进肠道益生菌生长。益生菌有助于免疫系统抵抗更危险的细菌;它们还能将营养成分分解;甚至还能控制身体储存脂肪。红曲增强免疫功能,含有癸烯鲲(COQ)是细胞代谢及细胞呼吸激活剂,能改善线粒体呼吸功能,促进氧化磷酸化反应。对免疫系统有非特异性增强作用,增强抗体,改善T细胞功能。红曲促进肠道蠕动及菌群平衡。红曲霉的代谢产物对乳酸菌生长有促进作用,使其存活时间明显延长;对大肠杆菌生长也有明显促进作用,可明显缓解便秘。
大黄:性味苦寒。入胃、大肠、肝经。《本经》:“下瘀血......,荡涤肠胃,推陈致新,通利水谷,调中化食,安和五脏。”大黄是一味“以通为补”保健佳味,具有通里攻下,活血化瘀之功效。可使肠道通畅、毒浊下泄,痰湿减少,血脉周流、增进食欲、增强体质。起到下泻作用的成分:几种葡萄糖甙和甙元,其中甙是主要的,甙下泻作用常强于其相应甙元。甙元主要是:蒽醌衍生物,包括大黄酚、大黄素、大黄酸和大黄素甲醚。
黑豆:性味甘、平。归经,入脾、肾经。《得配本草》:入足少阴经;《本草再新》:入心、脾、肾三经;《本草纲目》:黑豆入肾功多,故能治水、消胀、下气、制风热并活血解毒。黑豆含有优质蛋白质,含量高于瘦肉、蛋类及牛奶,有食品“蛋白质之王”美称。它还含有脂肪、碳水化合物、维生素B1、B2、尼克酸、胡萝卜素、钙、磷、铁、钾、硒酵素酶等。
本发明药物组分的用量是经过发明人进行大量摸索总结得出的,各组分用量为在下述重量份范围都具有较好疗效:
玉米9~10份、山药9~10份、鸡内金3~4份、白术3~4份、红曲2~3份,大黄0.5~1份、黑豆2~3份。
优选为:玉米10份、山药10份、鸡内金4份、白术4份、红曲3份,大黄1份、黑豆3份。
本发明药物可以采用中药制剂的常规方法制备成任何常规内服制剂。例如可以将这些原料药研成粉末混合均匀制成散剂口给药或者冲服;可以将这些原料药一起水煎,然后浓缩水煎液口服。
一种治疗厌食症与善饥症药物的制备方法,包括以下步骤:
1)玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2)称取山药及上述炮制好的玉米、鸡内金、白术、红曲,大黄和黑豆;
3)将上述原料药研磨成粒径为80~100目的细粉,混合均匀,即可。
所述原料药研磨成粒径为100目的细粉。
一种治疗厌食症与善饥症药物的制备方法,包括以下步骤:
1)玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2)称取山药及上述炮制好的玉米、鸡内金、白术、红曲,大黄和黑豆;
3)加水煎煮两次,每次加水量以没过药面为宜,合并两次煎液,过滤,获得滤液,即可获得本药物的有效成分。
所述步骤3)中将药物加水煎煮提取时,第一次加7倍药物重量的水,煎煮1.5小时,第二次加5倍药物重量的水,煎煮1小时。
也可直接购买经过炮制的玉米、鸡内金、白术、红曲,大黄和黑豆进行制备。
本发明药物的活性组分可以加入制备不同剂型时所需的各种常规辅料,如崩解剂、润滑剂、粘合剂等以常规的中药制剂方法制备成任何一种常用口服剂型,如丸剂、散剂、片剂、胶囊剂、口服液等。本发明药物的活性组分还可以加入适量蜂蜜或砂糖制造成糕点。
本发明药物集养生保健、治疗、康复于一体,可促进胃受纳,脾健运,肠吸收,通过调理人肠道菌群而达到有效治疗厌食症和善饥症的目的。玉米有丰富纤维素,可加强肠胃蠕动,将食物残渣尽速排除体外,促进新陈代谢;人口服鸡内金后胃液分泌量、酸度及消化力均见增高,其中消化力的增加出现较迟缓,维持也较久,服药后胃运动机能明显增强,表现在胃运动期的延长及蠕动液的增强,由于胃运动的增强,故胃排空率也大大加快;山药中的益生元是双歧杆菌、乳酸杆菌等生理性细菌所必需的营养和生长促进物质,使用益生元能增加有益菌,抑制有害菌,调节肠道菌群,使人体转为健康;大黄具有泻下作用和抗菌作用。本发明所述药物不仅仅杀死细菌,而且还能让致病细菌丧失致病能力。
具体实施方式
实施例1本发明药物的散剂制备
1)玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2)称取山药10克及上述炮制好的玉米10克、鸡内金4克、白术4克、红曲3克,大黄1克和黑豆3克;
3)将上述原料药研磨成粒径为100目的细粉,混合均匀,即可。
实施例2本发明药物的颗粒制剂制备
1)玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2)称取山药9克及上述炮制好的玉米9克、鸡内金3克、白术3克、红曲2克,大黄0.5克和黑豆2克;
3)将上述原料药研磨成粒径为80目的细粉,混合均匀;
4)加入蜂蜜作黏合剂,加入淀粉作填充剂,压制成颗粒剂。
实施例3 本发明药物的片剂制备
1)玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2)称取山药10克及上述炮制好的玉米9克、鸡内金4克、白术3克、红曲3克,大黄0.5克和黑豆3克;
3)将上述原料药研磨成粒径为90目的细粉,混合均匀;
4)加入辅料制成颗粒,并干燥,压制成片。
实施例4 本发明药物的口服液制备
1) 玉米、鸡内金、白术、红曲,大黄和黑豆分别进行炮制;
2) 称取山药9克及上述炮制好的玉米10克、鸡内金3克、白术4克、红曲2克,大黄1克和黑豆2克;
3)加水煎煮两次,第一次加224克水,煎煮1.5小时,第二次加水160克,煎煮1小时,合并两次煎液,过滤,获得滤液,即可获得本药物的有效成分。
试验例1本发明药物治疗厌食症的临床观察
病人:任某某,女,78岁。
症状:不食、不眠、不大便、疼痛剧烈、生活不能自理,腹盆腔巨大多发性囊性占位。
治疗方法:每日服用实施例1所述药物40克,分3次,早、中、晚饭前服用。
疗效:服药2天,通便,疼痛缓解,能安睡恢复正常饮食,继续用药1个月,生活能自理,此后若厌食或大便不通,再如法用药,又会正常用餐与通便,这样持续3年,肿瘤未见肿大。
试验例2 本发明药物治疗善饥症的临床观察
病人:林某某,女,50岁。
症状:贪食、失眠、胃痛、精神分裂症。
治疗方法:每日服用实施例2所述药物40克,分3次,早、中、晚饭前服用。
疗效:服药一星期,贪食症缓解,睡眠好转,腻苔消退,服药一个月,饮食正常,之后发病时用药,服药方法同上,一年多后精神状态好转。
试验例3 本发明药物治疗儿童厌食症的临床观察
病人:林某,男,1岁。
症状: 厌食、经常感冒。
治疗方法:每日服用实施例2所述药物12克,分3次,早、中、晚饭前服用。
疗效:服药半个月,饮食正常,用药2个月,未见感冒。
病人:林某,男,9个月。
症状: 厌食、流口水、夜眠磨牙。
治疗方法:每日服用实施例1所述药物12克,分3次,早、中、晚饭前服用。
疗效:服药7天,食量增,持续用药1个月,流口水消失,磨牙缓解。
病人:李某某,男,3岁。
症状: 厌食、经常扁桃体发炎、感冒发热。
治疗方法:每日服用实施例1所述药物14克,分3次,早、中、晚饭前服用。
疗效:服药10天,食欲增,持续用药3.5个月,未见扁桃体发炎。
病人:杨某某,男,14岁。
症状: 厌食、常腹泻、身材矮小。
治疗方法:每日服用实施例1所述药物20克,分3次,早、中、晚饭前服用。
疗效:服药15天,饮食、大便正常、身高增4厘米。
Claims (6)
1.一种治疗厌食症的药物,其特征在于它是由下列重量份的原料药制成:玉米9~10份、山药9~10份、鸡内金3~4份、白术3~4份、红曲2~3份,大黄0.5~1份、黑豆2~3份。
2.根据权利要求1所述的治疗厌食症的药物,其特征在于各原料药的用量为:玉米10份、山药10份、鸡内金4份、白术4份、红曲3份,大黄1份、黑豆3份。
3.权利要求1或2所述治疗厌食症药物的制备方法,其特征在于:包括以下步骤:
1)玉米、鸡内金、白术、红曲,大黄、黑豆分别进行炮制;
2)称取山药及上述炮制好的玉米、鸡内金、白术、红曲,大黄和黑豆;
3)将上述原料药研磨成粒径为80~100目的细粉,混合均匀,即可。
4.根据权利要求3所述的治疗厌食症药物的制备方法,其特征在于:所述原料药研磨成粒径为100目的细粉。
5.权利要求1或2所述治疗厌食症药物的制备方法,其特征在于:包括以下步骤:
1)玉米、鸡内金、白术、红曲,大黄、黑豆分别进行炮制;
2)称取山药及上述炮制好的玉米、鸡内金、白术、红曲,大黄和黑豆;
3)加水煎煮两次,每次加水量以没过药面为宜,合并两次煎液,过滤,获得滤液,即可获得本药物的有效成分。
6.根据权利要求5所述的治疗厌食症药物的制备方法,其特征在于:在步骤3)中将药物加水煎煮提取时,第一次加7倍药物重量的水,煎煮1.5小时,第二次加5倍药物重量的水,煎煮1小时。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100650432A CN101229331B (zh) | 2008-01-11 | 2008-01-11 | 一种治疗厌食症的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100650432A CN101229331B (zh) | 2008-01-11 | 2008-01-11 | 一种治疗厌食症的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229331A CN101229331A (zh) | 2008-07-30 |
| CN101229331B true CN101229331B (zh) | 2010-09-22 |
Family
ID=39896344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100650432A Expired - Fee Related CN101229331B (zh) | 2008-01-11 | 2008-01-11 | 一种治疗厌食症的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229331B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110938563B (zh) * | 2019-12-05 | 2020-09-29 | 北京伯恩世纪科技发展有限公司 | 一种乳酸菌bj-reborn001及其在制备抑制幽门螺旋杆菌的发酵液中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1194105A (zh) * | 1997-03-26 | 1998-09-30 | 侯玉壮 | 特制玉米精粉 |
| CN1579477A (zh) * | 2003-12-05 | 2005-02-16 | 曹明成 | 治疗小儿厌食的中药制剂处方、应用及制剂的制备方法 |
| CN1911308A (zh) * | 2006-08-18 | 2007-02-14 | 扬子江药业集团有限公司 | 一种治疗小儿厌食症药物及其制备方法 |
| CN100998714A (zh) * | 2006-12-28 | 2007-07-18 | 江蕾 | 一种治疗脾失健运型小儿厌食症的内服中药 |
-
2008
- 2008-01-11 CN CN2008100650432A patent/CN101229331B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1194105A (zh) * | 1997-03-26 | 1998-09-30 | 侯玉壮 | 特制玉米精粉 |
| CN1579477A (zh) * | 2003-12-05 | 2005-02-16 | 曹明成 | 治疗小儿厌食的中药制剂处方、应用及制剂的制备方法 |
| CN1911308A (zh) * | 2006-08-18 | 2007-02-14 | 扬子江药业集团有限公司 | 一种治疗小儿厌食症药物及其制备方法 |
| CN100998714A (zh) * | 2006-12-28 | 2007-07-18 | 江蕾 | 一种治疗脾失健运型小儿厌食症的内服中药 |
Non-Patent Citations (6)
| Title |
|---|
| 周金兰.小儿消化不良的中医辨治.甘肃中医 2.1990,(2),23、26-27. |
| 周金兰.小儿消化不良的中医辨治.甘肃中医 2.1990,(2),23、26-27. * |
| 彭芷美."疳证"的治疗体会.江西中医药25 3.1994,25(3),39-40. |
| 彭芷美."疳证"的治疗体会.江西中医药25 3.1994,25(3),39-40. * |
| 骆常义等.小儿厌食症病因及证治述要.中国临床医生33 1.2005,33(1),54-55. |
| 骆常义等.小儿厌食症病因及证治述要.中国临床医生33 1.2005,33(1),54-55. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101229331A (zh) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
| CN101797326B (zh) | 一种治疗肠鸣腹泻的中药制剂及其制备方法 | |
| CN101961473A (zh) | 一种治疗泄泻的中药组合物及其制备方法 | |
| CN104606612A (zh) | 一种解酒益肾压片糖果及其制备方法 | |
| CN101284122A (zh) | 一种抗水土不服的软胶囊 | |
| CN103638372B (zh) | 一种中药组合物及其制备方法和应用 | |
| CN101053621B (zh) | 一种治疗肥胖症的中药组合物及其制备方法 | |
| CN118434431A (zh) | 一种中药组合物及其制备方法与应用 | |
| CN106038820A (zh) | 一种改善功能性便秘的食药同源中药组合物及其制备方法 | |
| CN101427720A (zh) | 一种治疗糖尿病的高浓度溶泡茶及其制备方法 | |
| CN101249195B (zh) | 一种调理便秘消除淤毒的药物及其制备方法 | |
| CN101229331B (zh) | 一种治疗厌食症的药物及其制备方法 | |
| CN102743442B (zh) | 一种改善胃肠功能的中药组合物及制备方法 | |
| CN108813633A (zh) | 林蛙卵肽粉 | |
| CN103550494B (zh) | 一种中药组合物及其制备方法与含其制剂和应用 | |
| CN101953959A (zh) | 一种治疗糖尿病性胃麻痹的中药 | |
| CN102048896B (zh) | 一种改善胃肠功能的中药组合物及其制备方法 | |
| CN101468173A (zh) | 一种治疗小儿消化不良的中药组合物及其制备方法 | |
| CN105770705A (zh) | 一种治疗儿童功能消化不良的药物制剂及其用途 | |
| CN110496212A (zh) | 一种调理酒毒体质的中药组合物及其制备方法 | |
| CN104173745A (zh) | 一种滋补健身的蒙药 | |
| CN109349382A (zh) | 一种具有除寒解冷兼减肥养生功能的保健制剂 | |
| CN109260433A (zh) | 一种兼具养护脾胃和减肥养生功能的保健制剂 | |
| CN101181462B (zh) | 一种治疗小儿巨结肠症的药物及其制备方法 | |
| CN105851398A (zh) | 铁皮石斛养生茶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100922 Termination date: 20130111 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |